NASDAQ:AVTE - Nasdaq - US0080641071 - Common Stock - Currency: USD
2.68
0 (0%)
The current stock price of AVTE is 2.68 USD. In the past month the price increased by 5.93%. In the past year, price decreased by -86.79%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19 | 345.13B | ||
AMGN | AMGEN INC | 14.68 | 156.41B | ||
GILD | GILEAD SCIENCES INC | 13.76 | 132.82B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1756.9 | 130.98B | ||
REGN | REGENERON PHARMACEUTICALS | 13.51 | 65.46B | ||
ARGX | ARGENX SE - ADR | 339.55 | 39.39B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.24B | ||
ONC | BEIGENE LTD-ADR | N/A | 28.00B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.04B | ||
NTRA | NATERA INC | N/A | 20.40B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
BIIB | BIOGEN INC | 7.35 | 17.72B |
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Waltham, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2021-06-30. The firm is in the process of exploring strategic alternatives, which may include, but are not limited to, an acquisition, merger, reverse merger, business combination, liquidation or other transaction.
AEROVATE THERAPEUTICS INC
930 Winter Street, Suite M-500
Waltham MASSACHUSETTS US
CEO: Timothy P. Noyes
Employees: 51
Company Website: https://www.aerovatetx.com/
Investor Relations: https://ir.aerovatetx.com/
Phone: 16174432400
The current stock price of AVTE is 2.68 USD.
The exchange symbol of AEROVATE THERAPEUTICS INC is AVTE and it is listed on the Nasdaq exchange.
AVTE stock is listed on the Nasdaq exchange.
AEROVATE THERAPEUTICS INC (AVTE) has a market capitalization of 77.69M USD. This makes AVTE a Micro Cap stock.
AEROVATE THERAPEUTICS INC (AVTE) currently has 51 employees.
AEROVATE THERAPEUTICS INC (AVTE) has a support level at 2.62 and a resistance level at 2.72. Check the full technical report for a detailed analysis of AVTE support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AVTE does not pay a dividend.
AEROVATE THERAPEUTICS INC (AVTE) will report earnings on 2025-05-12, after the market close.
AEROVATE THERAPEUTICS INC (AVTE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.44).
ChartMill assigns a technical rating of 5 / 10 to AVTE. When comparing the yearly performance of all stocks, AVTE is a bad performer in the overall market: 90.58% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to AVTE. No worries on liquidiy or solvency for AVTE as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months AVTE reported a non-GAAP Earnings per Share(EPS) of -2.44. The EPS increased by 15.28% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -86.68% | ||
ROE | -91.1% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 49% to AVTE. The Buy consensus is the average rating of analysts ratings from 9 analysts.